

Special Issue

Advances in Follicular Lymphoma

Message from the Guest Editor

The therapeutic landscape in follicular lymphoma (FL) has seen many changes over the last decade, and many improvements have been reached in the understanding of the complex FL biology. Nonetheless, this indolent lymphoma is still considered incurable. It seems that histology, diagnosis and prognostic factors are insufficient support for clinical practice. Research and review papers on transformed FL are welcome. This Special Issue aims to capture new insights and relevant features of both FL biology and clinics (original research articles and reviews with original discussions) to help hematologists in patient risk stratification and in tailoring their treatment approach. We look forward to receiving your contributions.

Guest Editor

Dr. Lisa Argnani

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale,
Università di Bologna, Via Massarenti 9, 40138 Bologna, Italy

Deadline for manuscript submissions

closed (31 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/112510

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)